Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
La Jolla (LJPC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 58.44% and -10.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, March 02, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.
SAN DIEGO, April 06, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.
The market has been volatile in the last few months as the Federal Reserve finalized its rate cuts and uncertainty looms over trade negotiations with China. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by more than 10 percentage […]
SAN DIEGO, April 02, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.
As of late, it has definitely been a great time to be an investor in La Jolla Pharmaceutical.
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 5.10% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, April 13, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, March 13, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.
It's been a good week for La Jolla Pharmaceutical Company (NASDAQ:LJPC) shareholders, because the company has just...
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, April 03, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.
At two of them, the shares were sold in recent secondary offerings. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. The following are a few of significant insider purchases reported last week, all small-cap biotechs.
Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.Two-way Race The Watertown, Massachusetts-based company, which has a commercial antibiotic called Xerava to treat serious and life-threatening infections, is being pursued by La Jolla Pharmaceutical Company (NASDAQ: LJPC) after it signed a definitive agreement to be acquired by AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) in mid-March.La Jolla revealed in a filing it submitted a non-binding offer to acquire 100% of the equity of Tetraphase in an all-cash transaction.La Jolla offered for Tetraphase $22 million in cash, plus an additional $12.5 million potentially payable under contingent value rights, or CVRs, to be issued in the transaction.A contingent value right is a derivative instrument, with its value depending on some future event. If the event occurs by the specified date, then a holder of the CVR will get a pre-determined payout, mostly in cash."We are impressed with the growth potential of XERAVA and excited about the potential benefits of combining two companies focused on delivering important therapies to patients in the ICU," said Kevin Tang, Chairman of La Jolla in a letter addressed to the board of Tetraphase.Xerava, which was approved in August 2018, fetched Tetraphase revenues of $3.6 million in 2019 and $1.46 million in the fourth quarter of 2019.La Jolla said it plans to finance the proposed transaction with its cash on hand.Related Link: Attention Biotech Investors: Mark Your Calendar For These May PDUFA DatesAbout three weeks back, Tetraphase announced a definitive merger with AcelRx in a stock-for-stock transaction. The agreement provided for Tetraphase shareholders receiving 0.6303 share of AcelRx stock for each share they hold in Tetraphase, and a CVR, which will give the holders the right to receive aggregate payments of up to $12.5 million on achievement of future Xerava net sales milestones starting in 2021.The stock exchange ratio suggested valuation of $14.4 million at the close of trading March 13, a day before the deal was made public.AcelRx had said then it expects the deal to close in the second quarter. The boards of both companies vetted the transaction and certain stock and warrant holders holding an aggregate of approximately 31% of Tetraphase stock voting in favor of the deal.Merits Of The Offers La Jolla's superior cash offer cash might seem attractive at this juncture, as the world navigates through one of the worst crises it has ever faced."In our view, La Jolla's offer to Tetraphase hinges on an approximate $2.0M up-front premium to AcelRx's offer," H.C. Wainwright analyst Ed Arce said in a note. Despite La Jolla's higher consideration, he said Tetraphase might stick with the AcelRx offer.The terms of CVRs offered by both companies are same, except that La Jolla's CVRs would be paid in cash instead of cash or stock at the acquirer's option."We do not believe La Jolla's unsolicited competing bid is sufficiently compelling to Tetraphase to pull the company away from the current proposed transaction, especially given the amount of commitment and pre-close integration with AcelRx to date," Arce wrote in the note.The TTPH Move Tetraphase was up 89% to $2.63 at time of publication.Latest Ratings for TTPH DateFirmActionFromTo Mar 2020Gabelli & Co.DowngradesHoldSell Jan 2020Gabelli & Co.DowngradesBuyHold Oct 2019Gabelli & Co.UpgradesHoldBuy View More Analyst Ratings for TTPH View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
SAN DIEGO, April 07, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.
SAN DIEGO, Jan. 09, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to.
SAN DIEGO, May 04, 2020 -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve.